Compounding pharmacies fill millions of GLP-1 peptide prescriptions annually. Most test only what the FDA requires — and the FDA requires almost nothing.

1. The Compounding Boom

Since the FDA’s 2023 announcement that compounded semaglutide could meet an unmet medical need during the Wegovy shortage, 503A compounding pharmacies have become a major source of GLP-1 peptides for patients who cannot access or afford brand-name products.

The scale is enormous. Industry estimates suggest that compounded semaglutide and tirzepatide now account for 15–25% of all GLP-1 prescriptions in the United States. Yet the testing requirements for compounded peptides are a fraction of what commercial drug manufacturers must meet.

2. What 503A Compounding Actually Requires

Under section 503A of the FD&C Act, compounded drugs are exempt from FDA approval if they meet certain conditions. For peptide compounding, the key requirements are:

1. Bulk drug substance must come from a registered manufacturer
2. Compounding must be performed by a licensed pharmacist
3. Patient-specific prescription is required (no office-use stock)
4. Beyond-use date (BUD) must be assigned based on USP standards

What is not required:

• Identity testing of the bulk peptide before compounding
• Purity testing of the finished product
• Endotoxin testing for injectable products
• Stability studies to support the BUD
• Peptide content determination to ensure accurate dosing

The USP General Chapter <797> (sterile compounding) requires sterility testing for high-risk level compounding, but most peptide compounding is classified as medium-risk, which does not require terminal sterilization or sterility testing.

3. The Three Gaps

3.1 The Identity Gap

A compounding pharmacy may purchase bulk semaglutide powder from a supplier, receive a CoA declaring 99.2% purity, and compound it into patient prescriptions without ever verifying that the powder is actually semaglutide.

The FDA’s 2024–2025 inspection program found that:

• Approximately 15% of compounded semaglutide samples contained no detectable semaglutide
• An additional 10% contained semaglutide at less than 50% of labeled potency
• Some samples contained tirzepatide mislabeled as semaglutide

These findings are not from rogue operations — they are from licensed compounding pharmacies that relied on supplier CoAs without independent verification.

3.2 The Potency Gap

Even when the correct peptide is present, the dose may be wrong due to:

• Peptide content vs. purity confusion: A pharmacist weighing 5 mg of “99% pure” semaglutide acetate may actually be weighing only 4.2 mg of peptide
• Reconstitution errors: Inaccurate volume measurement, incomplete dissolution, or adsorption to vial surfaces
• Degradation: Peptide degraded during storage or shipping before compounding

The result is that two patients with identical prescriptions may receive doses differing by 20–40%.

3.3 The Safety Gap

Compounded peptides are injectable products. Without endotoxin and bioburden testing, patients are at risk of:

• Endotoxin reactions: Fever, chills, hypotension, and in severe cases, septic shock
• Microbial contamination: Local abscess, systemic infection
• Particulate matter: Embolism, inflammatory reactions

USP <797> requires garbing, cleanroom environments, and media fills for sterile compounding, but these measures reduce — they do not eliminate — microbial risk. End-product testing is the only definitive verification.

4. What Responsible Compounding Pharmacies Do

Leading compounding pharmacies have implemented testing programs that go far beyond minimum requirements:

These tests add approximately $50–$150 per batch to the cost of compounding. For a pharmacy producing 100 batches per month, that is $5,000–$15,000 per month — a significant cost, but trivial compared to the liability of a patient injury or regulatory enforcement action.

5. The Regulatory Trajectory

The regulatory environment for compounded peptides is tightening:

• FDA enforcement: The FDA has increased inspections of compounding pharmacies and issued warning letters for quality violations
• State boards of pharmacy: Several states have enacted specific peptide compounding regulations, including testing requirements
• Case law: Liability cases involving compounded drug injuries have resulted in significant judgments against pharmacies and their suppliers

The trajectory is clear: compounding pharmacies that do not implement robust testing programs will face increasing regulatory and legal risk.

6. Conclusion

The compounding gap is a patient safety crisis disguised as a cost-saving measure. The minimum requirements for 503A peptide compounding were not designed for high-volume injectable peptide products — they were designed for low-volume, individualized compounding of traditional drugs. Applying these minimal requirements to a market that dispenses millions of GLP-1 peptide doses annually is a regulatory failure that will eventually be corrected. In the meantime, responsible compounding pharmacies must implement their own testing programs to protect patients and their businesses.